帕博利珠单抗致免疫相关性结肠炎1例

One Case of Immune-related Colitis induced by Pembrolizumab

免疫检查点抑制剂在临床的使用范围逐渐扩大,可明显延长患者生存期,但其独特的免疫相关不良反应也应该引起人们的重视。本文报道1例60岁晚期肺癌男性患者在使用帕博利珠单抗注射液200 mg ivgtt后,出现严重腹泻,考虑为程序死亡因子受体-1抑制剂引起的免疫相关性结肠炎,予以激素冲击联合美沙拉嗪肠溶片对症治疗,最终好转。

Immune checkpoint inhibitors are widely used in clinic and can prolong the survival of patients significantly,but we should also be paid attention to their unique immune-related adverse reactions.This article reported a 60-year-old male patient with advanced lung cancer who developed severe diarrhea after taking 200 mg pembrolizumab,which was considered to be immune-associated colitis.Hormone shock combined with mesalazine enteric-coated tablets and other symptomatic treatments finally improved.